BARDA and Cue Health will collaborate to accelerate the development, validation, and manufacturing of a portable, molecular diagnostic test capable of detecting SARS-CoV-2, the virus that causes COVID-19, in less than 25 minutes using a simple nasal swab. In this public-private partnership, BARDA will provide approximately $13.6 million and expertise for development, validation and manufacturing of the test.
The test is part of the Cue Health Monitoring System, a portable device that not only can perform a molecular test but also can connect patients to telemedicine consultations through the system’s mobile health platform. The test on the Cue platform could potentially have significant impact on the management of the current pandemic by augmenting routine screening and testing to be conducted at point-of-care, including alternate care sites.
Having a test result in under 25 minutes could considerably improve the ability to manage care during a pandemic by helping to triage patients in a more efficient and effective manner.
This award is one component of BARDA’s rapidly expanding COVID-19 medical countermeasure portfolio; visit BARDA’s COVID-19 Portfolio to learn more.
About the Company:
Cue Health Inc. (“Cue”) is an ISO 13485 certified company founded by Ayub Khattak and Clint Sever focused on developing and manufacturing consumer and professional medical diagnostic products that can be used in clinical or at-home settings. Cue’s mission is to create tools that empower physicians and consumers by increasing their access to actionable health data. Cue’s first product, the Cue Health Monitoring System, is a connected diagnostic platform. The company is based in San Diego, CA.